ATE381316T1 - Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut - Google Patents

Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut

Info

Publication number
ATE381316T1
ATE381316T1 AT03757944T AT03757944T ATE381316T1 AT E381316 T1 ATE381316 T1 AT E381316T1 AT 03757944 T AT03757944 T AT 03757944T AT 03757944 T AT03757944 T AT 03757944T AT E381316 T1 ATE381316 T1 AT E381316T1
Authority
AT
Austria
Prior art keywords
application
aggregates
amphiphils
medications
vivo
Prior art date
Application number
AT03757944T
Other languages
English (en)
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea Ag filed Critical Idea Ag
Application granted granted Critical
Publication of ATE381316T1 publication Critical patent/ATE381316T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03757944T 2002-10-11 2003-10-09 Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut ATE381316T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery

Publications (1)

Publication Number Publication Date
ATE381316T1 true ATE381316T1 (de) 2008-01-15

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757944T ATE381316T1 (de) 2002-10-11 2003-10-09 Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut

Country Status (22)

Country Link
EP (5) EP1829527A3 (de)
JP (3) JP2006505619A (de)
KR (1) KR20050055723A (de)
CN (1) CN1703199B (de)
AT (1) ATE381316T1 (de)
AU (1) AU2003273977B2 (de)
BR (1) BR0315148A (de)
CA (1) CA2498938A1 (de)
DE (1) DE60318227T2 (de)
DK (1) DK1551370T3 (de)
EA (1) EA010407B1 (de)
ES (1) ES2298566T3 (de)
HK (1) HK1079113A1 (de)
HR (1) HRPK20050421B3 (de)
IS (1) IS7776A (de)
MX (1) MXPA05003744A (de)
NO (1) NO20052281L (de)
NZ (1) NZ538571A (de)
PL (1) PL377202A1 (de)
PT (1) PT1551370E (de)
SI (1) SI1551370T1 (de)
WO (1) WO2004032900A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
RU2491096C9 (ru) * 2007-09-13 2014-02-10 Басф Се Применение гидрофобин-полипептидов в качестве усилителя пенетрации
PL214538B1 (pl) 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
CN105434329A (zh) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
BR112012003834A2 (pt) 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
EP2712314A1 (de) * 2011-03-21 2014-04-02 Gregor Cevc Drogenfreie zusammensetzungen und verfahren zur verminderung peripherer entzündungen und schmerzen
DE112012001386T5 (de) * 2011-03-21 2013-12-19 Gregor Cevc Optimierte Präparate von sehr anpassungsfähigen Aggregaten
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
AU2013336430B2 (en) * 2012-10-26 2018-02-15 Oxford Nanopore Technologies Limited Droplet interfaces
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
EP3027219A1 (de) * 2013-07-31 2016-06-08 Sequessome Technology Holdings Limited Vesikel
AU2014324651B2 (en) * 2013-09-26 2019-03-14 National University Of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
WO2015060446A1 (ja) * 2013-10-25 2015-04-30 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
HRP20211669T1 (hr) 2015-06-30 2022-02-18 Sequessome Technology Holdings Limited Multifazni pripravci
WO2018187240A1 (en) * 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
EP4153564A1 (de) 2020-05-19 2023-03-29 Cybin IRL Limited Deuterierte tryptaminderivate und verfahren zur verwendung
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE4447277A1 (de) * 1994-12-30 1996-07-04 Hoechst Ag Stabilisierte, phosphormodifizierte Epoxidharze und ihre Verwendung
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
AU770803B2 (en) * 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis

Also Published As

Publication number Publication date
HRPK20050421B3 (en) 2007-06-30
AU2003273977A1 (en) 2004-05-04
JP2006505619A (ja) 2006-02-16
PL377202A1 (pl) 2006-01-23
NO20052281L (no) 2005-07-07
KR20050055723A (ko) 2005-06-13
BR0315148A (pt) 2005-08-16
IS7776A (is) 2005-03-30
EP1829528A3 (de) 2008-11-05
NO20052281D0 (no) 2005-05-10
EP1829527A2 (de) 2007-09-05
EA010407B1 (ru) 2008-08-29
HRP20050421A2 (en) 2005-12-31
EP1815847A2 (de) 2007-08-08
WO2004032900A8 (en) 2005-03-31
DE60318227D1 (de) 2008-01-31
EP1829527A3 (de) 2008-11-05
CN1703199B (zh) 2010-04-28
JP4555111B2 (ja) 2010-09-29
EP1815846A3 (de) 2008-10-22
JP2005213261A (ja) 2005-08-11
HK1079113A1 (en) 2006-03-31
AU2003273977B2 (en) 2007-07-12
CN1703199A (zh) 2005-11-30
PT1551370E (pt) 2008-02-07
WO2004032900A1 (en) 2004-04-22
ES2298566T3 (es) 2008-05-16
MXPA05003744A (es) 2005-09-20
DE60318227T2 (de) 2008-12-04
EP1815846A2 (de) 2007-08-08
NZ538571A (en) 2007-05-31
EP1815847A3 (de) 2008-11-05
CA2498938A1 (en) 2004-04-22
EA200500632A1 (ru) 2005-12-29
SI1551370T1 (sl) 2008-06-30
EP1551370A1 (de) 2005-07-13
EP1551370B1 (de) 2007-12-19
DK1551370T3 (da) 2008-03-03
EP1829528A2 (de) 2007-09-05
JP2009108070A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
ATE381316T1 (de) Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
PT637933E (pt) Metodo para tratamento de orgaos e tecidos
DE69512685D1 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
DE59309858D1 (de) Geschmacksmaskierte pharmazeutische Mittel
DE60142084D1 (de) Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
ECSP056076A (es) Sistema de suministro para droga y terapia celular
DE14189577T9 (de) Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat
DE60037192D1 (de) Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens
AR036402A1 (es) Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
Darko et al. Sleep disturbance in early HIV infection
WO2003072606A3 (en) Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
Colacurci et al. Time length of negativization of hCG serum values after either surgical or medical treatment of ectopic pregnancy
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
DE60322871D1 (de) Thaltende zubereitungen
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
SE9903183D0 (sv) Selektivt bindande och magnetiskt påverkbara nanopartiklar för medicinskt bruk
RU2004136095A (ru) Устройство для введения лекарственных веществ в полости органов размножения животных, например, коров
RU97103458A (ru) Способ приготовления препаратов для исследования микроскопической структуры костной ткани
ITMI20041871A1 (it) Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce
Gilden Crixivan warning: keep to three times a day
RU98103406A (ru) Способ лечения вибрационной болезни
RU2002109173A (ru) Способ лечения дистрофических заболеваний сетчатой оболочки глаза

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551370

Country of ref document: EP